You are here

Healthcare Economics


Abbott Laboratories is set to acquire St. Jude Medical in a cash and stock transaction valued at approximately $25 billion.



Recent Headlines

Medtronic hires Parkhill as CFO

Medtronic hired Karen L. Parkhill as the company’s chief financial officer (CFO) on May 4. She will also serve on Medtronic’s executive committee and report to CEO Omar Ishrak.

Impella growth helps Abiomed post strong yearly, quarterly results

Led by strong sales of its Impella devices, Abiomed reported on May 3 that its revenue increased 43 percent to $329.5 million during fiscal year 2016 compared with fiscal year 2015. For the fourth quarter, revenue increased 39 percent to $94.0 million, the 26th consecutive quarter that Abiomed’s revenue has increased by at least 10 percent year-over-year.

Abbott agrees to acquire St. Jude Medical in $25 billion deal

Abbott Laboratories is set to acquire St. Jude Medical in a cash and stock transaction valued at approximately $25 billion.

Boston Scientific’s revenue, profit increases in first quarter

During the first quarter of 2016, Boston Scientific reported sales of $1.964 billion, a 13 percent increase from the same period last year. The company had adjusted earnings per share of $0.28 per share, up from $0.21 per share a year ago. Boston Scientific also raised its revenue and earnings guidance for the full year.

St. Jude Medical’s revenue, earnings increase in first quarter

For the first quarter of fiscal year 2016, St. Jude Medical’s net sales increased 8 percent to $1.448 billion and its adjusted earnings increased 9 percent to $0.90 per share from the first quarter of last year.

Medtronic provides update on tender offer

Medtronic announced it had tendered approximately $5.8 billion in aggregate principal of outstanding debt securities as of 5:00 p.m. Eastern time on April 13, the early deadline for a previously announced tender offer.

Mean price of insulin increases nearly 200% from 2002 to 2013

From 2002 to 2013, the mean price of insulin increased 197 percent, from $4.34 per milliliter to $12.92 per milliliter, according to a survey of more than 27,000 people treated for diabetes.

Medtronic releases statement defending Covidien deal in wake of proposed tax regulations

After the U.S. Department of Treasury issued temporary and proposed regulations on tax inversions and other related topics, Medtronic announced in a news release on April 6 that the regulations “do not have a material financial impact on any transaction undertaken by the company.”

Medtronic announces cash tender offer for up to $2.75 billion in outstanding debt

Medtronic announced a cash tender offer on March 31 for up to $2.75 billion in aggregate purchase price for outstanding debt issued by Medtronic, Inc. and Covidien International Finance S.A., two of the company’s wholly-owned subsidiaries.

Edwards Lifesciences announces new member to its board of directors

Edwards Lifesciences Corp. announced that Steven R. Loranger had been appointed to its board of directors.